Evaluating Autologous Tumor-Infiltrating Lymphocyte Therapy with Chemotherapy and Aldesleukin for Advanced Non-Small Cell Lung Cancer
Led by National Cancer Institute (NCI) · Updated on 2026-10-20
85
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a new therapy for adults aged 18 to 72 with advanced non-small cell lung cancer NSCLC who have tumors that can be removed. The study aims to see if specially selected tumor-fighting white blood cells, called Tumor Infiltrating Lymphocytes TIL, can shrink NSCLC tumors and to assess the safety of this treatment. This approach builds on previous experiences with TIL therapy in melanoma and investigates its use in metastatic NSCLC.
Participants undergo several stages including initial evaluations with scans and lab tests, followed by surgery to remove a tumor for growing the TIL cells. Additional white blood cells may be collected through leukapheresis. After the cells are grown, patients receive a non-myeloablative lymphodepleting chemotherapy regimen with cyclophosphamide and fludarabine, then the TIL cells are infused intravenously, followed by either high-dose or low-dose aldesleukin. Hospitalization for about 4 weeks is required for treatment.
During the study, participants have regular follow-ups with physical exams, lab tests, and scans every 1 to 3 months for the first year and then every 6 months to 1 year if tumors continue to shrink. The study measures tumor response rate after cell infusion at multiple time points up to 2 years and monitors treatment side effects and cell characteristics for up to 2 to 4 years. Total study participation may include several years of monitoring and care.
CONDITIONS
Brief Title
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
Research Team
N
NCI SB Immunotherapy Recruitment Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
High-Dose Aldesleukin with TIL Therapy
Low-Dose Aldesleukin with TIL Therapy
What it is
Participants receive tumor-infiltrating lymphocyte (TIL) infusion following preparative chemotherapy and high-dose aldesleukin given intravenously every 8 hours for up to 9 doses.
Participants undergo TIL infusion after the same preparative regimen, then receive low-dose aldesleukin intravenously every 8 hours for up to 12 doses.
Role in the trial
Evaluates whether a higher dose of aldesleukin enhances TIL immunotherapy effect in advanced NSCLC.
Assesses if a lower dose of aldesleukin is effective while possibly lowering treatment-related adverse events.
Primary use
Designed to harness and boost the immune response using infused TIL with high-dose aldesleukin support to treat metastatic or unresectable NSCLC.
Uses TIL infusion complemented by a lower dose of aldesleukin, aiming to treat advanced NSCLC with potentially reduced toxicity.
How it is given or performed
After lymphodepleting chemotherapy, TILs are infused intravenously, then high-dose aldesleukin (720,000 IU/kg) is administered every 8 hours for up to 9 doses.
Following lymphodepleting chemotherapy and TIL infusion, low-dose aldesleukin (72,000 IU/kg) is provided intravenously every 8 hours for as many as 12 doses.
Evidence status
Clinical efficacy results for TIL therapy with high-dose aldesleukin in advanced NSCLC remain under study and are not yet posted. Published evidence in solid tumors shows TILs can provoke immune responses, and recent studies highlight tumor-specific T cell responses in epithelial cancers.
No clinical outcomes for TIL therapy with low-dose aldesleukin in NSCLC have been posted. Published studies focus primarily on TIL-based therapies and immune targets, with limited direct evidence for the lower dosing strategy in this setting.
Important limitations
High-dose aldesleukin can be associated with significant toxicities, such as capillary leak syndrome and organ dysfunction. Efficacy, tolerability, and optimal patient selection require more evidence in advanced NSCLC.
Reducing aldesleukin dose may improve tolerability, but it is uncertain whether immune function and TIL efficacy will be maintained. Evidence for the balance of safety and effectiveness remains limited.
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years - 72Years
All Genders
Eligibility Criteria
You may qualify if you...
Adults aged 18 to 72 years
Diagnosed with measurable metastatic or unresectable non-small cell lung cancer with at least one lesion that can be surgically removed
Up to 3 asymptomatic brain metastases less than 1 cm in size or stable treated brain metastases
Have received at least one prior systemic therapy and experienced disease progression
ECOG performance status of 0 or 1
Normal blood counts and liver and kidney function within specified limits
Negative for HIV and active hepatitis B or C
Willing to use birth control if of childbearing potential
Able to understand and sign informed consent
Able to sign durable power of attorney
Completed prior systemic therapy at enrollment
More than two weeks since any major bronchial bleeding palliation and recovered to grade 1 or less
Co-enrolled in protocol 03-C-0277
You will not qualify if you...
Nursing mothers
Need for continuing immunosuppressive treatment including steroids
Active systemic infections or major uncompensated medical illnesses
Major bronchial occlusion or bleeding not manageable by palliation
Primary immunodeficiency disorders such as Severe Combined Immunodeficiency or AIDS
Opportunistic infections
Severe allergic reactions to study agents
Low heart function (LVEF ≤ 45%) if clinical history indicates
Low lung function (FEV1 ≤ 50%) if clinical history indicates
More than 2 invasive chest procedures, poor exercise tolerance, age over 66, or other conditions that limit tolerance to high-dose aldesleukin (excludes high-dose arm only)
Participation in other investigational drug studies
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Initial outpatient evaluations including history, physical exams, scans, x-rays, and lab tests
Surgery and Tumor Collection
Duration - Varies by participant
Participants undergo surgery to remove tumor tissue that will be used to grow tumor-fighting cells for the treatment.
1 surgical procedure
Leukapheresis and Cell Growth
Duration - Several weeks for cell preparation
Participants may have white blood cells collected through leukapheresis to support growth of the tumor infiltrating lymphocytes in the lab.
1 leukapheresis procedure and lab processing
Treatment
Duration - Approximately 4 weeks
Participants receive chemotherapy to prepare the body, followed by infusion of the tumor-fighting cells and administration of either high-dose or low-dose aldesleukin. Hospitalization lasts about 4 weeks for treatment and monitoring.
Hospital stay with close monitoring and treatment administration
Follow-up
Duration - Up to several years
Participants return for regular physical exams, lab tests, and imaging to evaluate tumor response and monitor side effects. Visits occur every 1-3 months during the first year and then every 6 months to 1 year if tumors continue shrinking.
Clinic visits lasting up to 2 days each
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Evaluating Safety and Preliminary Efficacy of HS-IT101 Injection for Advanced Non-Small Cell Lung Cancer Treatment
Phase 12a Study of Intratumoral T3011 Alone and with Intravenous Pembrolizumab for Advanced or Metastatic Solid Tumors
Phase IbII Study of HMBD-001 With Cetuximab, With or Without Docetaxel, for Advanced Squamous Cell Cancers
Evaluation of Imaging, Safety, and Pharmacokinetics of 68GaGa-DWJ155 in Adults with Advanced Solid Tumors
Open-label Study of IV IDP-001 in Advanced or Metastatic Squamous Cell Lung Cancer and Other Solid Tumors
Phase 1 Study of VET3-TGI Alone and With Atezolizumab for Advanced Solid Tumors
Phase IbII Study of HB0025 Injection With Chemotherapy for Advanced Non-Small Cell Lung Cancer and Endometrial Cancer
Real-World Study of Tislelizumab Use and Outcomes in European Patients With Resectable or Advanced Non-Small Cell and Small Cell Lung Cancer
Investigating PF-08046876 Intravenous Treatment in Adults With Advanced Solid Tumors Including Bladder, Lung, Head and Neck, Esophageal, and Pancreatic Cancers
Phase IBII Study of Injectable SHR-A1811 Combined With Pyrotinib or SHR-1316 to Treat Advanced Non-small Cell Lung Cancer with HER2
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB-IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST).